HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.

Abstract
Pirarubicin tetrahydropyranyl adriamycin (THP-ADR) is an analogue of doxorubicin. This agent exhibits activity against some doxorubicin-resistant cell lines. We performed a phase II study of biweekly THP-COP [50 mg/m(2) pirarubicin, 750 mg/m(2) cyclophosphamide, 1.4 mg/m(2) vincristine (2.0 mg maximum) on day 1, and 100 mg/body predonisolone on days 1-5] in patients with peripheral T-cell lymphoma (PTCL). Seventeen patients with newly diagnosed PTCL were enrolled. Histological diagnoses were of PTCL, not otherwise specified (n = 5), or angioimmunoblastic T-cell lymphoma (n = 12). All diagnostic specimens including those of the historical control group were centrally reviewed by hematological pathologists. All patients received six cycles of biweekly THP-COP. The patient group included 13 male and 4 female patients, with a median age of 62 years. The median follow-up time in surviving patients was 30 months. Overall response rate was 94% with 15 cases of complete remission (88%). The 3-year progression-free survival and overall survival rates were 57% and 75%, respectively. The most frequent adverse events associated with biweekly THP-COP were leukocytopenia (100%), neutropenia (100%), and lymphopenia (100%), followed by alopecia (92%) and anaemia (88%). All of these occurred only transiently, and the patients subsequently recovered. Biweekly THP-COP is a safe and promising therapy for patients with newly diagnosed PTCL. This study is registered in a public database (UMIN000010485).
AuthorsNaoto Tomita, Fumio Kodama, Naoko Tsuyama, Seiji Sakata, Kengo Takeuchi, Daisuke Ishibashi, Satoshi Koyama, Yoshimi Ishii, Wataru Yamamoto, Hirotaka Takasaki, Maki Hagihara, Hideyuki Kuwabara, Masatsugu Tanaka, Chizuko Hashimoto, Etsuko Yamazaki, Hideyuki Koharazawa, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo
JournalHematological oncology (Hematol Oncol) Vol. 33 Issue 1 Pg. 9-14 (Mar 2015) ISSN: 1099-1069 [Electronic] England
PMID24519501 (Publication Type: Clinical Trial, Phase II, Journal Article)
CopyrightCopyright © 2014 John Wiley & Sons, Ltd.
Chemical References
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • pirarubicin
Topics
  • Adolescent
  • Adult
  • Aged
  • Alopecia (chemically induced)
  • Anemia (chemically induced)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Doxorubicin (administration & dosage, adverse effects, analogs & derivatives)
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Leukopenia (chemically induced)
  • Lymphoma, T-Cell, Peripheral (drug therapy)
  • Lymphopenia (chemically induced)
  • Middle Aged
  • Neutropenia (chemically induced)
  • Prognosis
  • Survival Analysis
  • Treatment Outcome
  • Vincristine (administration & dosage, adverse effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: